Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Anthracycline Chemotherapy in TNBC with Residual Disease
NCT04437160Phase 2Recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Feb 2020
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin, pirarubicin and cyclophosphamide in triple-negative breast cancer (TNBC) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Recurrence Free Survival at 5 years. Started Feb 2020; status: recruiting.
02
Drugs
epirubicinpirarubicincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04437160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04437160.